Senior Consultant Surgeon & Head of Surgery at SKH. Leads Upper GI & Bariatric Service. Fellow of RCS Edinburgh & Glasgow and World Obesity Federation. PhD in Biomedical Engineering. Expert in surgical innovation and obesity treatment.
Bariatric Surgery
Clinician's Perspective: • Mechanical Restriction: The procedure involves the surgical removal of approximately 80% of the stomach, leaving a narrow, tubular "sleeve" about the size of a banana. • Hormonal Modulation: Beyond physical size, the surgery significantly reduces the production of hunger-regulating hormones, which helps suppress appetite
Understanding Obesity
Clinician's Perspective: • Limitation of BMI: Body Mass Index (a weight-to-height ratio used to categorize body mass) is a population-level tool that often fails to distinguish between lean muscle and adipose tissue (body fat) in individuals. • Clinical Staging Utility: The Edmonton Obesity Staging System (a five-
Understanding Obesity
Clinician's Perspective: • Mortality Link: Two-thirds (67.5%) of deaths associated with a high body mass index are specifically attributable to Cardiovascular Disease (heart and blood vessel conditions). • While Body Mass Index (a value derived from the mass and height of a person) is the gold standard for
Understanding Obesity
Clinician's Perspective: • Global Projections: Researchers estimate that by 2030, 60% of the world’s population will be overweight or obese, with obesity currently accounting for 44% of all diabetes cases. • The "diabesity" Phenomenon: The term "diabesity" describes the nearly inseparable relationship between obesity and
Understanding Obesity
Clinician's Perspective: • The true driver of colorectal cancer: body fat distribution. • The Waist-to-Hip Ratio (WHR) (a measure of central obesity) proved to be a significantly more accurate predictor of colorectal cancer than total body weight or BMI. • The "Normal Weight" Illusion: The data revealed
Understanding Obesity
Clinician's Perspective: • Central Obesity Trends: The prevalence of abdominal obesity continues to rise, with the crude rate recorded at 43.6% in the 2023-2024 cycle, compared to 40.6% in 2019-2020. Central Obesity is linked to poor metabolic health. • 22.8% were in the high-risk
Understanding Obesity
Clinician's Perspective: • Muscle helps improve metabolic health. A 1.9% to 3.3% increase in muscle mass is linked to a 4.1% reduction in fat mass and a 5.8% drop in fasting glucose levels. • With resistance training, the body diverts glucose and amino acids away from
Understanding Obesity
Clinician's Perspective: • Obesity significantly increases the risk of cancer in the gastric cardia (the top part of the stomach where it meets the food pipe), but not in other areas of the stomach. • Individuals classified as obese (a Body Mass Index of 30 or higher) showed a 57%
Understanding Obesity
Clinician's Perspective: • Research involving over 496,000 participants suggests that obesity functions as an important driver of accelerated aging, with nearly 60% of the link between weight and mortality being mediated through age-related cellular diseases. • Telomere Attrition: Obesity is consistently associated with the shortening of Telomeres (the
Lifestyle & Wellness
Clinician's Perspective: • Bidirectional Feedback: The relationship between sleep and weight is a "two-way street" where poor sleep drives weight gain, and excess adiposity (the state of having too much body fat) compromises sleep quality. • Hormonal Dysregulation: Sleep deprivation disrupts the signaling of Leptin (the hormone
Pharmacotherapy
Clinician's Perspective: • Combined Potency: Bupropion combined with Naltrexone demonstrated superior weight reduction compared to Bupropion monotherapy (the use of a single drug). • Absolute Weight Loss: The meta-analysis, involving over 22,000 participants, revealed a mean weight reduction of 3.67 kg across the intervention groups compared to
Pharmacotherapy
Clinician's Perspective: • Synergistic Weight Loss: Combining phentermine and topiramate-ER (extended-release) provides a more robust weight reduction than either drug used alone by targeting different metabolic pathways. • Significant Results: In the EQUIP trial involving 1,267 participants, the high-dose group achieved an average weight loss of